With global demand for GLP-1-based drugs rising, Indian CDMOs are ramping up peptide capabilities ahead of key patent ...

For older adults with diabetes, there is no clear evidence to suggest that the incidence of dementia differs for those using ...

In major diabetes research news just published in Nature Communications, scientists at the Diabetes Research Institute (DRI) at the University of Miami have shown that a small peptide, called THR-123, ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18, offering both glycemic control and weight loss ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

MIT researchers have developed an implant that releases glucagol under the control of external sensors to protect diabetes ...

Discontinuation of GLP-1 receptor agonists suggested before conception rather than between start of pregnancy and end of first trimester.

A population-based cohort study emulating a target trial estimated the effect of glucagon-like peptide-1 receptor agonists ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key role in the inflammatory response in plaque psoriasis.

SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...